Next Article in Journal
Interaction of Cholesterol with Perfringolysin O: What Have We Learned from Functional Analysis?
Next Article in Special Issue
Targeting Metastasis with Snake Toxins: Molecular Mechanisms
Previous Article in Journal
A Supercluster of Neutralizing Epitopes at the Interface of Ricin’s Enzymatic (RTA) and Binding (RTB) Subunits
Previous Article in Special Issue
Molecular Dynamics Simulation Reveals Specific Interaction Sites between Scorpion Toxins and Kv1.2 Channel: Implications for Design of Highly Selective Drugs
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Toxins 2017, 9(12), 379; https://doi.org/10.3390/toxins9120379

Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa

1,2,3
and
1,2,3,*
1
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA
2
Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA
3
James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Steve Peigneur
Received: 18 October 2017 / Revised: 14 November 2017 / Accepted: 21 November 2017 / Published: 23 November 2017
(This article belongs to the Special Issue Toxins in Drug Discovery and Pharmacology)
View Full-Text   |   Download PDF [547 KB, uploaded 23 November 2017]   |  

Abstract

Cholera toxin B subunit (CTB) is a mucosal immunomodulatory protein that induces robust mucosal and systemic antibody responses. This well-known biological activity has been exploited in cholera prevention (as a component of Dukoral® vaccine) and vaccine development for decades. On the other hand, several studies have investigated CTB’s immunotherapeutic potential in the treatment of inflammatory diseases such as Crohn’s disease and asthma. Furthermore, we recently found that a variant of CTB could induce colon epithelial wound healing in mouse colitis models. This review summarizes the possible mechanisms behind CTB’s anti-inflammatory activity and discuss how the protein could impact mucosal inflammatory disease treatment. View Full-Text
Keywords: cholera toxin B subunit; mucosal immunity; immunomodulation; anti-inflammatory; retrograde trafficking; GM1 ganglioside cholera toxin B subunit; mucosal immunity; immunomodulation; anti-inflammatory; retrograde trafficking; GM1 ganglioside
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Royal, J.M.; Matoba, N. Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa. Toxins 2017, 9, 379.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top